Purpose To provide recommendations on appropriate use of breast tumor biomarker assay
results to guide decisions on adjuvant systemic therapy for women with early-stage invasive�…

Abstract The NCI-MATCH (Molecular Analysis for Therapy Choice) trial (NCT02465060) was
launched in 2015 as a genomically driven, signal-seeking precision medicine platform trial�…

The pivotal phase II and III Herceptin� trials proved the efficacy and safety of second-or third-
line single-agent Herceptin and first-line Herceptin in combination with chemotherapy�…

PURPOSE: To evaluate the efficacy and safety of first-line, single-agent trastuzumab in
women with HER2-overexpressing metastatic breast cancer. PATIENTS AND METHODS�…

Cells with distinct phenotypes including stem-cell-like properties have been proposed to
exist in normal human mammary epithelium and breast carcinomas, but their detailed�…

We developed a computational method to characterize aneuploidy in tumor samples based
on coordinated aberrations in expression of genes localized to each chromosomal region�…

Purpose To provide recommendations on the appropriate use of breast tumor biomarker
assay results to guide decisions on systemic therapy for metastatic breast cancer. Methods A�…

Cyclin D1 is overexpressed in the majority of human breast cancers. We previously found
that mice lacking cyclin D1 are resistant to mammary carcinomas triggered by the ErbB-2�…

The effects of primary tumors on the host systemic environment and resulting contributions of
the host to tumor growth are poorly understood. Here, we find that human breast carcinomas�…

Purpose: Trastuzumab combined with chemotherapy improves outcomes for women with
human epidermal growth factor receptor 2 (HER2) overexpressing advanced breast cancer�…